Adlai Nortye gets rights to Novartis' buparlisib

Chinese immunotherapy company Adlai Nortye Biopharma Co. Ltd. (Hangzhou, China) gained exclusive, worldwide rights to cancer candidate buparlisib (BKM120) from Novartis AG (NYSE:NVS; SIX:NOVN). Financial terms were not disclosed.

Adlai Nortye has global rights to develop and commercialize buparlisib, except for "certain limited rights" Novartis retained "to comply with ongoing contractual obligations," Novartis spokesperson Eric Althoff told BioCentury. Althoff declined to provide details...